CD34 and atrial fibrillation: Three consecutive randomized and double-blinded trials have demonstrated the safety and efficacy of the reduction in CCS class 3–4 refractory angina from obstructive CAD via the delivery of intramyocardial CD34+ stem cells, and a pooled analysis of these studies showed significant improvements in AF and TET and a reduction of mortality.